Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis
- PMID: 35085379
- PMCID: PMC10200307
- DOI: 10.1093/brain/awac019
Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis
Abstract
Blood-brain barrier (BBB) breakdown and immune cell infiltration into the CNS are early hallmarks of multiple sclerosis (MS). The mechanisms leading to BBB dysfunction are incompletely understood and generally thought to be a consequence of neuroinflammation. Here, we have challenged this view and asked if intrinsic alterations in the BBB of MS patients contribute to MS pathogenesis. To this end, we made use of human induced pluripotent stem cells derived from healthy controls and MS patients and differentiated them into brain microvascular endothelial cell (BMEC)-like cells as in vitro model of the BBB. MS-derived BMEC-like cells showed impaired junctional integrity, barrier properties and efflux pump activity when compared to healthy controls. Also, MS-derived BMEC-like cells displayed an inflammatory phenotype with increased adhesion molecule expression and immune cell interactions. Activation of Wnt/β-catenin signalling in MS-derived endothelial progenitor cells enhanced barrier characteristics and reduced the inflammatory phenotype. Our study provides evidence for an intrinsic impairment of BBB function in MS patients that can be modelled in vitro. Human iPSC-derived BMEC-like cells are thus suitable to explore the molecular underpinnings of BBB dysfunction in MS and will assist in the identification of potential novel therapeutic targets for BBB stabilization.
Keywords: blood–brain barrier; human induced pluripotent stem cells; immune cell migration; multiple sclerosis; permeability.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
B.E. received a grant from Biogen to study extended dosing of Natalizumab on T-cell migration across the BBB and a grant from CSL Behring to investigate the molecular underpinnings of BBB dysfunction in neurological disorders. H.N., B.D.G., S.P.P., E.V.S. and B.E. are inventors on an international patent application related to the EECM-BMEC-like cells (publication number WO/2022/072354).
Figures
References
-
- Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391:1622–1636. - PubMed
-
- Kermode AG, Thompson AJ, Tofts P, et al. . Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990;113:1477–1489. - PubMed
-
- Filippi M, Rovaris M, Capra R, et al. . A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain. 1998;121:2011–2020. - PubMed
